Skip to main content

Table 1 Patient characteristics

From: TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

Characteristic Letrozole alone, n = 25 Letrozole/bevacizumab, n = 50 p value
Age (years)
 Median (range) 65 (50.4–86.3) 61.4 (50.4–81.9) NSD
Race, n (%)
 White 20 (80) 42 (84) NSD
 Black 3 (12) 6 (12) NSD
 Hispanic 1 (4) 2 (4) NSD
 Others 1—Asian (4)  
Clinical tumor stage, n (%)
 IIA 9 (36) 16 (32) NSD
 IIB 7 (28) 21 (42) NSD
 IIIA 9 (36) 8 (16) NSD
 IIIB 5 (10) NSD
Nodal status, n (%)
 N0 9 (36) 21 (42) NSD
 N+ 16 (64) 29 (58) NSD
Tumor type, n (%)
 Invasive ductal carcinoma 16 (64) 29 (58) NSD
 Invasive lobular carcinoma 5 (20) 13* (26) NSD
 Invasive mixed carcinoma 4 (16) 7 (14) NSD
 Others 1—mucinous (2) NSD
Histologic grade, n (%)
 Grade I 6 (24) 13 (26) NSD
 Grade II 19 (76) 29 (58) 0.042
 Grade III 8 (16) 0.025
  1. *Includes one patient with concurrent separate invasive mucinous carcinoma
  2. NSD no significant difference